Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
02/2003
02/26/2003CN1399565A Propellant free spray-on skin patch composition for improving wound healing and for drug administration
02/26/2003CN1399562A Method of treating lupus based on antibody affinity and screening methods and compositions for use thereof
02/26/2003CN1399561A Conjugate having cleavable linkage for use in liposome
02/26/2003CN1399560A Novel albumin-free factor VIII formulations
02/26/2003CN1399559A Micro-cluster liquids and methods of making and using them
02/26/2003CN1399554A Method and compositions for inhibiting adhesion formation
02/26/2003CN1399543A Controlled release composition comprising nimesulide
02/26/2003CN1399542A Pharmaceutical carrier formulation
02/26/2003CN1399541A Colloidal suspension of submicronic particles as vectors for active principles and method for preparing same
02/26/2003CN1399540A Aerosol composition comprising formoterol
02/26/2003CN1399539A Adjuvant comprising polyxyethylene alkyl ether or ester and at least one nonionic surfactant
02/26/2003CN1399533A Improved transdermal contraceptive delivery system and process
02/26/2003CN1399520A Phytosterol and phytostanol compositions
02/26/2003CN1398582A Local acne treating device
02/26/2003CN1102154C Acylated gamma-cyclodextrin mixer, its prep. and use
02/26/2003CN1102068C Process for preparing calcium carboxymethyl cellulose
02/26/2003CN1102046C Oral antibacterial composition
02/26/2003CN1102045C Novel compositions containing lipids and stabilizing agent
02/26/2003CA2454667A1 Remedies for mammary cancer
02/25/2003WO2002026233A1 Infusion of ciprofloxacin having reduced acid content and being stable in storage
02/25/2003USRE38008 Peptides hormones, steroid hormones and conjugates thereof are disclosed. Enhanced delivery to target cells of antibodies or fragments thereof or other receptor-mediated delivery system, such as peptide, specific for a population of cells of a
02/25/2003US6525192 Low-substituted hydroxypropyl cellulose and process for producing same
02/25/2003US6525102 Increasing storage stability of interleukin-2 by incorporating free base form arginine and succinic acid
02/25/2003US6525058 1-ethyl methylester 4-((3- (p-(carboxyamidino)phenyl) -2-oxo-5-oxazolidinyl)methyl)-1-piperazineacetate; Gantofiban; antagonistic action to Glycoprotein GPIIb/IIIa receptor; oily base; gantofiban citrate
02/25/2003US6525057 Sustained release ranolazine formulations
02/25/2003US6524823 Vasopermeability-enhancing conjugates
02/25/2003US6524805 Cell expressing said receptors contacted with test compound; if induced response is inhibited by tamoxifen, but not by internal estrogen receptor antagonist then test compound is an agonist
02/25/2003US6524623 Therapeutic compositions and methods of use thereof
02/25/2003US6524617 Vinyl alcohol-vinylpyrrolidone copolymer and microcrystalline silicified cellulose for fillers of pharmaceutical tablets; hardness at low compression force, and low friability, without icreasing size
02/25/2003US6524613 Hepatocellular chimeraplasty
02/25/2003US6524612 Adhesive cooling composition and process for its preparation
02/25/2003US6524608 Intravesical drug delivery system
02/25/2003US6524607 Nontoxic, nonglucocorticoid, biocompatible, biodegradable, controlled release material
02/25/2003US6524606 Bioerodible polyorthoesters containing amine groups
02/25/2003US6524595 Dermopharmaceuticals.
02/25/2003US6524592 Oil in water emulsion of white mineral oil, mannitol oleate emulsifier with clostridium and possibly chorynebacterium antigens for prevention of clostridial diseases of sheep (and lambs)
02/25/2003US6524583 Inhibit angiogenesis and induce tumor regression, and have improved safety due to their specificity
02/25/2003US6524576 Probiotic composition; veterinary feed additive; food additive; microorganisms dispenser; eliminating an oil pollution; restoring organic fumes degrading microorganism population in a biofilter
02/25/2003US6524575 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
02/25/2003US6524570 Polyethylene glycol modified interferon therapy
02/25/2003US6524569 Anionic-cationic polyion complexes comprising zwitterionic monomer component
02/25/2003US6524564 Hair treatment or skin cosmetic composition which comprises at least one water soluble or water dispersible polymer formed from urethane (methacrylate) containing siloxane groups, and at least one cosmetic auxiliary
02/25/2003US6524560 Use of substituted vinyltetrahydronaphthalenes and vinyl-benzotetrahydropyrans as light protection agents
02/25/2003US6524557 Aerosol formulations of peptides and proteins
02/25/2003US6524556 Tricyclic compound dispersed in liquefied hydrofluoroalkane propellant; medium-chain fatty acid triglyceride as dispersant
02/25/2003US6524552 Contrast agents
02/25/2003CA2420556A1 Infusion of ciprofloxacin having reduced acid content and being stable on storage
02/25/2003CA2171852C Budesonide pellets with a controlled release pattern and process for producing them
02/25/2003CA2113080C Topical composition containing penciclovir
02/23/2003CA2355348A1 Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
02/20/2003WO2003014331A1 Erythrocytic cells and method for preserving cells
02/20/2003WO2003014316A2 Immunomodulatory compositions, formulations, and methods for use thereof
02/20/2003WO2003014305A2 Eukaryotic cells and method for preserving cells
02/20/2003WO2003014155A2 Labelled conjugates of p17 protein and their use in aids diagnosis
02/20/2003WO2003014076A2 Bi-directional synthesis of oligoguanidine transport agents
02/20/2003WO2003014069A1 Fluoro linkers and their use as linkers for enzyme-activated drug conjugates
02/20/2003WO2003013633A1 Inhalation device with a pharmaceutical composition
02/20/2003WO2003013617A2 Conjugates of macrocyclic metal complexes with biomolecules and the utilization thereof for producing agents for use in nmr diagnosis and radiodiagnosis and radiotherapy
02/20/2003WO2003013614A1 Collagen-containing oral preparations, drugs and quasi drugs
02/20/2003WO2003013613A1 Percutaneous absorption type medicinal preparation
02/20/2003WO2003013612A1 Polysaccharide-containing compositions and use thereof
02/20/2003WO2003013611A1 Percutaneous absorption preparations
02/20/2003WO2003013610A2 Surfactant compounds and uses thereof
02/20/2003WO2003013602A1 Inhibitors of her3 activity
02/20/2003WO2003013593A2 Composite superimmunogen for bi-functional vaccine use for the treatment of illnesses associated with a stromal tissue disorder
02/20/2003WO2003013587A1 Compositions for vascular occlusion
02/20/2003WO2003013573A1 Polypeptide conjugates with extended circulating half-lives
02/20/2003WO2003013566A1 High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
02/20/2003WO2003013549A2 Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals
02/20/2003WO2003013548A1 Medical composition for external use for dermatosis
02/20/2003WO2003013529A1 Paroxetine glycyrrhizinate
02/20/2003WO2003013513A1 Stable emulsion composition
02/20/2003WO2003013511A1 Integrin inhibitors for the treatment of eye diseases
02/20/2003WO2003013508A1 Therapeutic agent for depletion of an unwanted protein population from plasma
02/20/2003WO2003013498A2 Nitrate ester-cyclodextrin complexes for treating diseases, particularly coronary diseases
02/20/2003WO2003013489A1 Treatment of nail infections with no
02/20/2003WO2003013479A1 Compositions and methods to prevent abuse of opioids
02/20/2003WO2003013478A2 Method of encapsulating an active substance
02/20/2003WO2003013477A1 Drug release system for controlled therapy
02/20/2003WO2003013476A1 Compositions and methods to prevent abuse of opioids
02/20/2003WO2003013474A1 Nanoparticulate formulations of fenofibrate
02/20/2003WO2003013473A1 Stabilized oral suspension formulation
02/20/2003WO2003013472A1 Aqueous dispersion comprising stable nanoparticles of a water-insoluble active and an excipient like middle chain triglycerides (mct)
02/20/2003WO2003013470A1 Composition comprising paroxetine and a pharmaceutically acceptable glycyrrhizinate salt
02/20/2003WO2003013445A1 Nanocapsules containing a steroid for cosmetic compositions
02/20/2003WO2003013440A2 Treatment and prevention of heat shock protein-associated diseases and conditions
02/20/2003WO2003013438A2 Nutrient therapy for immuno-compromised patients
02/20/2003WO2003013421A2 Pharmaceutical composition comprising a water/oil/water double microemulsion incorporated in a solid support
02/20/2003WO2003013277A1 Chitosan-containing powder
02/20/2003WO2002098951A3 Lipid-polymer-conjugates
02/20/2003WO2002098427A3 Sustained-release analgesic compounds
02/20/2003WO2002096927A3 Ribozyme based treatment of female reproductive diseases
02/20/2003WO2002094200A3 Pulmonary administration of chemically modified insulin
02/20/2003WO2002094173A3 Tamper resistant oral dosage form
02/20/2003WO2002089815A3 Disinfecting and solubilizing steroid compositions
02/20/2003WO2002078602A3 Transdermal delivery of pergolide
02/20/2003WO2002076398A3 Improved forms of pharmaceutically active agents and method for manufacture thereof
02/20/2003WO2002072003A3 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour
02/20/2003WO2002070016A8 Catecholate beta-lactam conjugates, method for producing the same and the use thereof
02/20/2003WO2002067998A3 Devices and methods for the treatment of cancer
1 ... 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 ... 1712